Prognostic Performance of a Modified HFA-ICOS Tool for Prediction of Cardiovascular Complications in Cancer Patients
Authors' conclusion
The tool stratifies CVD risk in cancer patients and may guide tailored follow-up and cardioprotection.
Study context
- Population
- Cancer patients from the third follow-up of the Trøndelag Health study (HUNT), diagnosed within 4 years of participation, followed through 2023
- Participants
- 2,290 patients
- Comparison
- Modified HFA-ICOS risk categories
- Outcome
- Composite of:
- MI
- HF hospitalisation
- Stroke
- Cardiovascular disease (CVD) mortality
- Follow-up
- Median 6.9 years
Performance
As reported in the abstract
CVD incidence (MI, HF hospitalisation, stroke or CVD mortality) by modified HFA-ICOS risk category
C-statistic
0.696
95% CI 0.674–0.718
Further findings
C-statistic, anthracycline-treated (subgroup)
- C-statistic
- 0.746 (95% CI: 0.676-0.812)
Event rates within low-to-moderate group, by points
- 0-1 points
- 6% to 8%
- 3-4 points
- 24% to 27%
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Prognostic Performance of a Modified HFA-ICOS Tool for Prediction of Cardiovascular Complications in Cancer Patients. JACC Adv. Published 14 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →